Survodutide

Survodutide is a novel long-acting dual glucagon-like peptide-1 (GLP-1) receptor and glucagon receptor (GCGR) agonist. Survodutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GCG receptor (GCGR) or the GLP-1R. Survodutide is a synthetic peptide glucagon analog rather than an analog of oxyntomodulin, unlike other dual GLP-1/glucagon dual agonists. Survodutide binds human and mouse GCGR and GLP-1R and stimulates insulin secretion in isolated mouse, rat and perifused human pancreatic islets. Survodutide is used in studies of obesity and type 2 diabetes (T2D) and is designed enhancing energy expenditure and fat metabolism and decreasing food intake. Survodutide comprises a 29 amino acid linear synthetic peptide conjugated to a C18 fatty diacid moiety through a hydrophilic linker at the lysine residue at position 24. Due to this moiety, the compound is highly bound to albumin in the plasma which prolongs its half-life. It contains one non-coded amino acid residue (Ac4c, 1-Aminocyclobutane-1-carboxylic acid) at position 2, well established as the site of proteolytic activity for dipeptidyl peptidase-4.